View Financial HealthSinil Pharmaceutical 배당 및 자사주 매입배당 기준 점검 2/6Sinil Pharmaceutical 은(는) 현재 수익률이 3.75% 인 배당금 지급 회사입니다.핵심 정보3.8%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.모든 업데이트 보기Recent updatesNew Risk • Mar 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.3% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (9.3% net profit margin). Market cap is less than US$100m (₩67.6b market cap, or US$45.2m).공고 • Mar 12Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South KoreaReported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩20.6b (flat on 3Q 2024). Net income: ₩2.61b (down 5.9% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공고 • Mar 08Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South KoreaReported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩240 (vs ₩300 in 3Q 2023)Third quarter 2024 results: EPS: ₩240 (down from ₩300 in 3Q 2023). Revenue: ₩20.6b (down 19% from 3Q 2023). Net income: ₩2.77b (down 20% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.분석 기사 • Aug 12Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) EarningsSinil Pharmaceutical Co., Ltd.'s ( KOSDAQ:012790 ) price-to-earnings (or "P/E") ratio of 6.8x might make it look like a...Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).New Risk • Nov 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩82.1b market cap, or US$63.5m).Reported Earnings • Nov 20Third quarter 2023 earnings released: EPS: ₩300 (vs ₩213 in 3Q 2022)Third quarter 2023 results: EPS: ₩300 (up from ₩213 in 3Q 2022). Revenue: ₩25.4b (up 25% from 3Q 2022). Net income: ₩3.47b (up 41% from 3Q 2022). Profit margin: 14% (up from 12% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩329 (vs ₩217 in 1Q 2022)First quarter 2023 results: EPS: ₩329 (up from ₩217 in 1Q 2022). Revenue: ₩21.8b (up 22% from 1Q 2022). Net income: ₩3.80b (up 51% from 1Q 2022). Profit margin: 17% (up from 14% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Oct 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩9,912, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 2.1%. The fair value is estimated to be ₩10,911, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,150, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 67% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,260, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩11,600, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 168% over the past three years.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩15,850, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 50% over the past three years.분석 기사 • Mar 11Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?With its stock down 41% over the past three months, it is easy to disregard Sinil Pharmaceutical (KOSDAQ:012790). It is...분석 기사 • Feb 13Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?It hasn't been the best quarter for Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) shareholders, since the share...분석 기사 • Jan 17Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?The big shareholder groups in Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) have power over the company. Insiders...Is New 90 Day High Low • Jan 15New 90-day low: ₩19,000The company is down 19% from its price of ₩23,592 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩20,150, the stock is trading at a trailing P/E ratio of 26.1x, down from the previous P/E ratio of 30.9x. This compares to an average P/E of 29x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 141%.분석 기사 • Dec 22Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 15% share price gain to ₩25,800, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 28.1x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.분석 기사 • Nov 26Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at Sinil Pharmaceutical's (KOSDAQ:012790) recent performance, when its stock...Is New 90 Day High Low • Nov 11New 90-day low: ₩20,300The company is down 23% from its price of ₩26,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 18New 90-day low: ₩24,300The company is down 8.0% from its price of ₩26,500 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, A012790 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: A012790 의 배당금 지급이 증가했지만 회사는 5 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Sinil Pharmaceutical 배당 수익률 vs 시장A012790의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A012790)3.8%시장 하위 25% (KR)1.6%시장 상위 25% (KR)4.7%업계 평균 (Pharmaceuticals)1.2%분석가 예측 (A012790) (최대 3년)n/a주목할만한 배당금: A012790 의 배당금( 3.75% )은 KR 시장에서 배당금 지급자의 하위 25%( 1.62% )보다 높습니다.고배당: A012790 의 배당금( 3.75% )은 KR 시장에서 배당금 지급자의 상위 25%( 4.66% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A012790 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 44.9% )로 A012790 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 17:58종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sinil Pharmaceutical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).
Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.
New Risk • Mar 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.3% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (9.3% net profit margin). Market cap is less than US$100m (₩67.6b market cap, or US$45.2m).
공고 • Mar 12Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South Korea
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩20.6b (flat on 3Q 2024). Net income: ₩2.61b (down 5.9% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공고 • Mar 08Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South Korea
Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩240 (vs ₩300 in 3Q 2023)Third quarter 2024 results: EPS: ₩240 (down from ₩300 in 3Q 2023). Revenue: ₩20.6b (down 19% from 3Q 2023). Net income: ₩2.77b (down 20% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 12Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) EarningsSinil Pharmaceutical Co., Ltd.'s ( KOSDAQ:012790 ) price-to-earnings (or "P/E") ratio of 6.8x might make it look like a...
Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
New Risk • Nov 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩82.1b market cap, or US$63.5m).
Reported Earnings • Nov 20Third quarter 2023 earnings released: EPS: ₩300 (vs ₩213 in 3Q 2022)Third quarter 2023 results: EPS: ₩300 (up from ₩213 in 3Q 2022). Revenue: ₩25.4b (up 25% from 3Q 2022). Net income: ₩3.47b (up 41% from 3Q 2022). Profit margin: 14% (up from 12% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩329 (vs ₩217 in 1Q 2022)First quarter 2023 results: EPS: ₩329 (up from ₩217 in 1Q 2022). Revenue: ₩21.8b (up 22% from 1Q 2022). Net income: ₩3.80b (up 51% from 1Q 2022). Profit margin: 17% (up from 14% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Oct 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩9,912, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.
Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 2.1%. The fair value is estimated to be ₩10,911, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,150, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 67% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,260, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩11,600, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 168% over the past three years.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩15,850, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 50% over the past three years.
분석 기사 • Mar 11Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?With its stock down 41% over the past three months, it is easy to disregard Sinil Pharmaceutical (KOSDAQ:012790). It is...
분석 기사 • Feb 13Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?It hasn't been the best quarter for Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) shareholders, since the share...
분석 기사 • Jan 17Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?The big shareholder groups in Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) have power over the company. Insiders...
Is New 90 Day High Low • Jan 15New 90-day low: ₩19,000The company is down 19% from its price of ₩23,592 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩20,150, the stock is trading at a trailing P/E ratio of 26.1x, down from the previous P/E ratio of 30.9x. This compares to an average P/E of 29x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 141%.
분석 기사 • Dec 22Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 15% share price gain to ₩25,800, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 28.1x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.
분석 기사 • Nov 26Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at Sinil Pharmaceutical's (KOSDAQ:012790) recent performance, when its stock...
Is New 90 Day High Low • Nov 11New 90-day low: ₩20,300The company is down 23% from its price of ₩26,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 18New 90-day low: ₩24,300The company is down 8.0% from its price of ₩26,500 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.